Understanding genetic cancer susceptibility just became more precise for families carrying specific inherited mutations. A comprehensive analysis of over 1,300 individuals from families with CTNNA1 gene variants reveals that not all mutations in this cancer-predisposition gene carry equal risk, fundamentally changing how genetic counselors should assess and advise patients.
The research demonstrates that truncating CTNNA1 variants—those that create shortened, non-functional proteins—confer an eightfold higher risk of diffuse gastric cancer compared to non-truncating variants that produce altered but potentially functional proteins. Through laboratory studies using CRISPR gene-editing technology and fruit fly models, scientists confirmed that truncating variants trigger cellular mechanisms that degrade the faulty genetic messages, effectively eliminating protective αE-catenin protein from cells. Meanwhile, carriers of truncating CTNNA1 mutations face a fivefold lower gastric cancer risk and eightfold lower lobular breast cancer risk compared to those with CDH1 mutations, another well-studied hereditary cancer gene.
This granular risk stratification represents a significant advancement in precision medicine for hereditary cancer syndromes. While CDH1 mutation carriers often undergo prophylactic stomach removal due to high cancer penetrance, CTNNA1 carriers may benefit from more nuanced surveillance protocols. The findings challenge the one-size-fits-all approach to hereditary diffuse gastric cancer management, suggesting that mutation type and location within the gene should guide clinical decisions. However, the study's focus on European and American populations limits generalizability, and longer follow-up periods are needed to validate lifetime risk estimates across different CTNNA1 variant subtypes.